Lincoln Pharma Standalone December 2022 Net Sales at Rs 133.77 crore, up 11.58% Y-o-Y
14-03-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs10-03-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011q
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Munjal Mahendrabhai Patel & PACs06-03-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Hansaben Arvindbhai Patel17-02-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication with respect to the un-audited financial results (Standalone and Consolidated) of the Company for the quarter and nine months ended December 31, 2022.10-02-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Financial Results Of The Company
To Consider and approved un-audited financial results (Standalone and Consolidated) of the Company along with the limited review reports for the quarter and nine months ended on December 31, 2022.09-02-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Outcome for OUTCOME OF BOARD MEETING
Outcome of the Board Meeting held today09-02-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Board Meeting Intimation for Board Meeting Intimation For Inter-Alia To Consider And Approve The Un-Audited Financial Results For The Quarter And Nine-Months Ended On December 31, 2022.
LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/02/2023 ,inter alia, to consider and approve the Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and nine-months ended on December 31, 2022 along with any other business, if any.31-01-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Intimation Of Reconstitution Of Committees Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Consequent upon cessation of Mr. Ishwarlal Ambalal Patel, Independent Director of the Company due to his untimely demise, the Board of Directors has reconstituted the committees effective from conclusion of the meeting of Board of Directors held today i.e. on January 31, 2023.31-01-2023
LINCOLN PHARMACEUTICALS LTD. - 531633 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to provision of Regulation 74 (5) of the SEBI (Depositories and Participants) Regulations, 2018, we hereby submit the confirmation certificate received from Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) for the Quarter Ended December 31, 2022.06-01-2023